Barrett featured in Genetic Engineering and Biotechnology News
Aug 2, 2021
CRB’s Mike Barrett interviewed for “Facility Expansions Are on the Rise” in Genetic Engineering and Biotechnology News (GEN), a 40-year-old publication focusing on the topics of bioprocessing, cancer, drug discovery, genome editing, OMICs, and translational medicine.
Increase in approvals by the FDA
In 2020, the FDA approved 53 novel drugs. To date for 2021, 31 have been approved, not including the many that have been granted emergency use authorization. This is a major increase from the average 22 approvals prior to 2017.
The growing demand for novel therapies, paired with unique business drivers, are what Barrett attributes the increase of facility expansions to.
Lean design and construction principles
CRB incorporates Lean design and construction principles on projects to reduce waste and deliver greater value to clients.
TAKT is a project-completion strategy whereby steps occurring at different rates are harmonized temporally to reduce chaos and uncertainty.
Innovation drives business decisions
Barrett explains that CRB evaluates many innovative process technologies during early planning phases to lock in the technology selections specified by the customer’s business criteria, so the technologies that stick and eventually are utilized typically have a unique connection to that business case.
Read the full article in GEN here.